Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

/files/Articles/741326/fonc-11

Alveolar progenitor cells and the origin of lung cancer - Sainz de Aja - 2021 - Journal of Internal Medicine - Wiley Online Library

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study, BMC Cancer

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer

Diagnostics, Free Full-Text

Toward personalized treatment approaches for non-small-cell lung cancer

Resistance to targeted cancer therapies. Drug resistance can occur at

Frontiers Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies

Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology, Genome Medicine

Cancers, Free Full-Text

Frontiers HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies

A Look at NSCLC and Its Current and Emerging Therapies

Cells, Free Full-Text

Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications

Cancers, Free Full-Text